The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AEROVATE THERAPEUTICS INC | COM | 008064107 | 1,228 | 66,977 | SH | OTR | 1 | 0 | 66,977 | 0 | |
| ALPINE IMMUNE SCIENCES INC | COM | 02083G100 | 13,318 | 1,484,693 | SH | OTR | 1 | 0 | 1,484,693 | 0 | |
| BELLUS HEALTH INC NEW | COM NEW | 07987C204 | 19,619 | 2,851,588 | SH | OTR | 1 | 0 | 2,851,588 | 0 | |
| CYMABAY THERAPEUTICS INC | COM | 23257D103 | 4,318 | 1,388,505 | SH | OTR | 1 | 0 | 1,388,505 | 0 | |
| ELEVATION ONCOLOGY INC | COM | 28623U101 | 25 | 10,000 | SH | OTR | 1 | 0 | 10,000 | 0 | |
| IMMUNOGEN INC | COM | 45253H101 | 7,346 | 1,543,259 | SH | OTR | 1 | 0 | 1,543,259 | 0 | |
| KINNATE BIOPHARMA INC | COM | 49705R105 | 7,798 | 692,508 | SH | OTR | 1 | 0 | 692,508 | 0 | |
| MERUS N V | COM | N5749R100 | 23,625 | 893,527 | SH | OTR | 1 | 0 | 893,527 | 0 | |
| OTONOMY INC | COM | 68906L105 | 72 | 30,000 | SH | OTR | 1 | 0 | 30,000 | 0 | |
| PARDES BIOSCIENCES INC | COM | 69945Q105 | 11,861 | 1,642,834 | SH | OTR | 1 | 0 | 1,642,834 | 0 | |
| PASSAGE BIO INC | COM | 702712100 | 327 | 105,504 | SH | OTR | 1 | 0 | 105,504 | 0 | |
| PIERIS PHARMACEUTICALS INC | COM | 720795103 | 3,443 | 1,136,319 | SH | OTR | 1 | 0 | 1,136,319 | 0 | |
| THESEUS PHARMACEUTICALS INC | COM | 88369M101 | 4,114 | 356,827 | SH | OTR | 1 | 0 | 356,827 | 0 | |
| TRAVERE THERAPEUTICS INC | COM | 89422G107 | 10,609 | 411,680 | SH | OTR | 1 | 0 | 411,680 | 0 | |